May 2020 Slide Summaries

Slide 1
Generally normal film, mild leucopaenia, occasional atypical lymphocyte

Slide 2
Generally normal film, basophilia

Slide 3
Blasts present. Neutropaenia, basophilia, anisocytosis, thrombocytopaenia. Known AML

Slide 4
Blastoid form of mantle cell lymphoma. Additional myelodysplastic features

Slide 5
Reactive, plasmacytoid lymphocytes

Slide 6
Reactive lymphocytes Thrombocytopaenia Malaria - trophozoites (see case study opposite)

Monthly Digital Case study

May 2020 Slide 6

Presentation
Male (27 years old) Patient hospitalized following a return from Togo (a duration of approximately 3 months). Difficulty eating, body aches, fluctuating fever, fatigue.

FBC Results

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>7.2 (10^3/mm³)</td>
<td>Neutrophils 81.1%</td>
</tr>
<tr>
<td>RBC</td>
<td>3.38 (10^6/mm³)</td>
<td>Lymphocytes 12.9%</td>
</tr>
<tr>
<td>HGB</td>
<td>116 (g/L)</td>
<td>Monocytes 2.9%</td>
</tr>
<tr>
<td>HCT</td>
<td>34.5 (%)</td>
<td>Eosinophils 0.7%</td>
</tr>
<tr>
<td>MCV</td>
<td>102 (fl)</td>
<td>Basophils 1.4%</td>
</tr>
<tr>
<td>MCH</td>
<td>34.5 (pg)</td>
<td></td>
</tr>
<tr>
<td>MCHC</td>
<td>33.7 (g/dL)</td>
<td></td>
</tr>
<tr>
<td>PLT</td>
<td>46 (10^3/mm³)</td>
<td></td>
</tr>
</tbody>
</table>

Reactive/plasmacytoid lymphocytes

Slide review
Examination of the blood film confirms thrombocytopaenia. The most distinctive feature is the presence of some deeply basophilic lymphocytes, some with an offset nucleus, characteristic of plasma cells. Examination of the red cell/platelet images, reveals a number of trophozoites (ring-forms) of Malaria. The trophozoites were compact. No schizonts or gametocytes or multiple parasitaemia.

Diagnosis
The trophozoites appear characteristic of Plasmodium Falciparum. Standard staining for malaria is Giemsa staining at pH7.2, not MGG at pH6.8. Confirmatory malaria screening films should be reviewed. Thrombocytopaenia is also indicative of Malaria. Atypical lymphocytes have been observed in Malaria but it is not possible to rule co-morbidities. Viral studies recommended.
Introduction
Mantle Cell Lymphoma is a rare sub-type of Non-Hodgkin’s Lymphoma. It is a B-cell lymphoma that develops from an area of the lymph node known as the mantle zone. It accounts for 2-7 percent of NHLs in the US and Europe and is characterized by a t(11;14)(q13;q32) translocation.

Clinical Presentation
The disease primarily affects men over the age of 50 year presenting with normally painless lymphadenopathy. Many affected individuals have widespread disease at diagnosis, with involved regions often including multiple lymph nodes, the spleen, and, potentially, the bone marrow, the liver, and/or regions of the gastrointestinal tract. Individuals may also present with non-specific symptoms or symptoms relating to bone marrow infiltration.

Genetics
Cytogenetic analyses have revealed that MCL is closely associated with the t(11;14)(q13;q32). This translocation juxtaposes Ig heavy chain gene (IGH) sequences with the BCL-1 locus, leading to up-regulation of the CCND1 gene and consequently to an overexpression of cyclin D1. The presence of this translocation is required for diagnosis. Other mutations are usually present.

Laboratory Findings
The peripheral blood may be normal on presentation but bone marrow infiltration is common with mantle cell lymphoma.

- In advanced disease with bone marrow involvement, there may be anaemia, neutropenia and/or thrombocytopenia.
- The abnormal ‘Mantle cells’ may be seen in the peripheral blood. There are several variants of mantle cell including the ‘blastoid’ cells illustrated above.
- Serum Lactate Dehydrogenase (LDH) is frequently raised and may indicate rapidly proliferating disease.
- Uric acid may be elevated.
- Cells are CD5 positive.

Treatment and Prognosis
Current treatment regimes include chemotherapy such as R-CHOP (rituximab in combination with cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin) and prednisolone). Ibrutinib is used in relapsed cases and early disease. Stem cell transplantation.

Prognosis is relatively poor but 15% of cases follow a more indolent course, similar to CLL.
Auer Rods
A diagnostic morphology feature.

Introduction
Auer rods are seen in certain white blood cells and can be used to assist in the classification of leukaemias. They are named after the American Physiologist John Auer, although they were first described in 1905 by a Canadian physicist named Thomas McCrae.

What are they?
Auer rods (or Auer bodies) are large, crystalline cytoplasmic inclusion bodies, which form elongated red-staining needles. They are composed of fused lysosomes and contain peroxidase, lysosomal enzymes and large crystalline inclusions.

What do they indicate?
They may be seen in myeloid blast cells during acute myeloid leukemia, acute promyelocytic leukaemia (M3), and high grade myelodysplastic syndromes and myeloproliferative disorders cells under microscopic examination.

The identification of Auer rods is very significant, as when found, they can confirm the presence of myeloblasts, indicating the presence of a non-lymphocytic (myeloid) leukaemia. This differentiation is important, as treatments vary between lymphoblastic and myeloblastic leukaemia.

Auer rods can cause disseminated intravascular coagulation (DIC) due to the granules in the malignant promyelocytes containing a substance which rapidly activates the coagulation cascade. As many traditional chemotherapy agents cause cell lysis and the release of procoagulant substances, this puts the patient at a higher risk of disseminated intravascular coagulation (DIC).

This Month’s Top Morphology Tip
LOW POWER!

Don’t forget to use your low power objective when examining a manual blood film. It’s ideal for getting and overview of the slide - quality, cellularity, cell distribution, as well as selecting the best viewing area for a WBC differential.